Compare Novo Nordisk A/S (NVO) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Consumer Staples Select Sector SPDR Fund — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Consumer Staples Select Sector SPDR Fund trades at $83.43 (market cap $13.50B). The key difference: Novo Nordisk A/S is far larger — about 12.2× Consumer Staples Select Sector SPDR Fund's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Consumer Staples Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| NVO | XLP | |
|---|---|---|
Market Cap | $165.31B | $13.50B |
Volume | 11,432,838 | 14,599,953 |
Sector | Health | — |
52-Week High | $63.98 | $90.00 |
52-Week Low | $35.29 | $75.61 |
Typical Hold Time | 116 Days | 72 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
XLP trades at $83.42, up 2.11% with a bullish technical signal supported by moving averages and oscillators. The ETF shows strong relative performance against discretionary peers, gaining 6.6% year-to-date while XLY declined over 7%. Analyst consensus is unanimously bullish with 100% buy ratings. Recent news highlights XLP's defensive characteristics amid economic uncertainty and its competitive expense ratio advantage over peer funds.
The outlook remains positive given XLP's defensive positioning in consumer staples, low 0.08% expense ratio, and strong technical momentum. However, risks include sensitivity to interest rate movements and potential consumer spending slowdown. The ETF's proximity to resistance at $84 suggests near-term consolidation may precede further upside if bullish momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
